Author of

• 12544

  +

  P3.08 - Poster Session 3 - Radiotherapy (ID 199)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Radiation Oncology + Radiotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12566

    +

    P3.08-022 - Survival analysis of Hypo-fractionated Radical Radiotherapy for the treatment of Non-Small-Cell Lung Cancer using 55Gy in 20 fractions: The North Wales Cancer Centre Experience (ID 2651)

    09:30 - 09:30  |  Author(s): G. Thomas
    • Abstract

    Background
    Hypo fractionated radical radiotherapy using 55 Gy in 20 fractions is one of the most commonly used radical radiotherapy regimens in the UK. The shorter overall treatment time has the radio-biological advantage of minimal re-population. Despite its popularity in UK, there is paucity of supporting data in the reported literature. We present the mature outcome data of this regimen based on the single centre experience in North Wales Cancer Centre,UK.

    Methods
    A retrospective case note analyses of Non-Small-Cell Lung Cancer patients who underwent radical radiotherapy using 55Gy in 20 fraction (fraction size that 2.75 Gy/fraction), between 2001 and 2011, was carried out. We included the patients who had the total dose reduced to 52.5 Gy in 20 fractions to allow for normal tissue constraints. Patients receiving concurrent chemoradiation and adjuvant radiotherapy after surgical resection were excluded. The records were updated using the national registry of death in Wales. Univariate analyses of the effects of different subgroups on overall survival were performed.

    Results
    

    Table 1. Stage and Histological distribution

    		No of patients
    stage	IA	27
    	IB	35
    	IIA	8
    	IIB	30
    	IIIA	52
    	IIIB	66
    	IV	1
    	Unknown	3
    Histology	NOS	37
    	Non-Squamous	44
    	Squamous	95
    	Unknown	46

    Total 222 patients (128 males, 94 females) underwent radical radiotherapy between 2001 and 2011. Median follow up period was 267 weeks (range 74-637). Mean age at diagnosis was 68 yr (41-91). The stage and histological distribution is shown in table 1. Of the stage III patients 81 had induction chemotherapy before the radiotherapy. The median survival of the whole group was 124 weeks (95% CI 105-141) and the survival by histology and stages is shown in table 2. The good 2 yr but poor 5 yr OS of the Stage I patients may reflect their poorer general health at presentation that rendered them medically inoperable. Table 2. Overall survival by Stage and Histological Subgroups

    		Median OS in Weeks (95% C.I.)	2 yr OS	5 yr OS
    stage	stage 1	135 (116-210)	68%	28%	p= 0.47
    	stage 2	135 (80-264)	58%	42%
    	stage 3	105 (85-141)	50%	27%
    Histology	NOS	73 (60-102)	30%	10%	p= 0.0004
    	Non-Squamous	131 (114-216)	67%	25%
    	Squamous	130 (97-162)	57%	35%
    	Unknown	191 (131-325)	67%	38%

    Conclusion
    Radical Radiotherapy using 55 Gy in 20 fractions is a highly effective form of treatment for early and locally advanced stages of Non-Small-Cell Lung Cancer with results comparable to isofractionated radiotherapy published in the literature.